- Home
- JAZZ vs JLL Comparison
JAZZ vs JLL Comparison
Compare JAZZ & JLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JAZZ | JLL |
|---|---|---|
| Founded | 2003 | 1997 |
| Country | Ireland | United States |
| Employees | N/A | 48000 |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.1B | 13.6B |
| IPO Year | 2007 | 1997 |
Fundamental Metrics
Financial Performance| Metric | JAZZ | JLL |
|---|---|---|
| Price | $244.79 | $369.79 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 22 | 12 |
| Target Price | $295.86 | ★ $415.90 |
| AVG Volume (30 Days) | ★ 771.2K | 532.0K |
| Earning Date | 11-02-2026 | 10-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 45.13 |
| EPS | 0.04 | ★ 14.73 |
| Revenue | $1,618,693,000.00 | ★ $26,115,600,000.00 |
| Revenue This Year | $12.59 | $10.78 |
| Revenue Next Year | $5.11 | $7.71 |
| P/E Ratio | $6,151.50 | ★ $25.46 |
| Revenue Growth | N/A | ★ 11.45 |
| 52 Week Low | $136.56 | $259.83 |
| 52 Week High | $266.38 | $395.79 |
Technical Indicators
Market Signals| Indicator | JAZZ | JLL |
|---|---|---|
| Relative Strength Index (RSI) | 65.72 | 61.85 |
| Support Level | $236.70 | $285.97 |
| Resistance Level | $250.49 | $393.84 |
| Average True Range (ATR) | 7.18 | 12.71 |
| MACD | 4.64 | 4.35 |
| Stochastic Oscillator | 95.81 | 73.86 |
Price Performance
Historical ComparisonAbout JAZZ Jazz Pharmaceuticals plc (Ireland)
Jazz Pharmaceuticals is an Ireland-domiciled biopharmaceutical firm focused primarily on treatments for sleeping disorders and oncology. Jazz has nine approved drugs across neuroscience and oncology indications; its portfolio includes Xyrem and Xywav for narcolepsy, Zepzelca for the treatment of metastatic small cell lung cancer, Rylaze for acute lymphoblastic leukemia, and Vyxeos for acute myeloid leukemia. In May 2021, Jazz acquired GW Pharmaceuticals and gained its leading product, Epidiolex for the treatment of severe, rare forms of epilepsy.
About JLL Jones Lang LaSalle Incorporated
Jones Lang LaSalle is a global commercial real estate services and investment management company that helps clients buy, build, occupy, manage, and invest in property across office, industrial, retail, multifamily, hotel, and data center assets. For over 200 years, clients have trusted JLL, a Fortune 500 company, tracing its roots to firms including LaSalle Partners (founded in Chicago in 1968) and the centuries-old London firm Jones Lang Wootton, which merged in 1999 to form the modern JLL. Today, the firm is a leading global commercial real estate services and investment management company with operations in over 80 countries and a global workforce of more than 113,000, as of early 2026.